raloxifene hydrochloride has been researched along with Cancer of Cervix in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, SH; Lambert, PF; Spurgeon, ME | 1 |
| Chung, SH; Lambert, PF | 1 |
| Cuzick, J | 1 |
| Fogarty, EA; Kraus, WL; Matulis, CK | 1 |
| Kammerer, S | 1 |
| Christodoulakos, G; Creatsas, G; Lambrinoudaki, I; Politi, E; Sergentanis, TN; Sioulas, V | 1 |
6 other study(ies) available for raloxifene hydrochloride and Cancer of Cervix
| Article | Year |
|---|---|
Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy.
Topics: Animals; Biomarkers, Tumor; Cell Proliferation; Disease Models, Animal; Epithelium; Estrogen Receptor alpha; Estrogens; Female; Genitalia, Female; Humans; Mice; Mice, Transgenic; Neoplasm Recurrence, Local; Prognosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists.
Topics: Animals; Antineoplastic Agents, Hormonal; Disease Models, Animal; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, Transgenic; Papillomavirus Infections; Raloxifene Hydrochloride; Uterine Cervical Neoplasms | 2009 |
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).
Topics: Adenocarcinoma; Breast Neoplasms; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Incidence; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Papillomavirus Vaccines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Sample Size; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Cervical Neoplasms | 2010 |
Activation of estrogen receptor α by raloxifene through an activating protein-1-dependent tethering mechanism in human cervical epithelial cancer cells: a role for c-Jun N-terminal kinase.
Topics: Carrier Proteins; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation; Genes, Reporter; Glucuronosyltransferase; HeLa Cells; Humans; Luciferases; Matrix Metalloproteinase 1; Mitogen-Activated Protein Kinase 8; Neoplasms, Glandular and Epithelial; Phosphoric Monoester Hydrolases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Transcription Factor AP-1; Uterine Cervical Neoplasms | 2012 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene.
Topics: Aged; Cadherins; Cervix Uteri; Epithelial Cells; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Immunohistochemistry; Metaplasia; Middle Aged; Norpregnenes; Papanicolaou Test; Postmenopause; Raloxifene Hydrochloride; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaginal Smears | 2008 |